Program
GB-115
Its studies are mostly in Anxiety Disorders · Adjustment Disorders, led by Valenta Pharm JSC.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Valenta Pharm JSC | 21 open or running | phase 4since Feb 17, 2025 | Oct 14, 2022 | Dec 31, 2027phase 4 · NCT06843044 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2022First study: phase 3 study in Anxiety DisordersFirst studyNCT05586789 · 220 enrolled · Russian Federation
- Feb 17, 2025Phase 4 study in Anxiety DisordersNCT06843044 · 250 planned · Russia
Ahead
- Dec 31, 2027Primary completion: phase 4 study in Anxiety DisordersNCT06843044
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06843044Anxiety Disorders · Russia | 4 | Recruiting | Dec 31, 2027 | 250 |
| NCT05586789Anxiety Disorders · Russian Federation | 3 | Completed | Nov 22, 2022 | 220 |
How it is read
Names in the registry
- “Ranquilon”, 2 entries
Codes read as this program: GB115.
Conditions, from the studies’ own filings
- Anxiety Disorders, 1 study
- Adjustment Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.